Categories Earnings, Health Care

Exact Sciences Corp. (EXAS): Q4 2019 Earnings Snapshot

— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.

— Total revenues were $295.6 million, vs. $283 million expected.

— Screening revenues increased 60% to $229.4 million.

— Cologuard test volume rose 63% to 477,000.

— Average Cologuard recognized revenue per test was $481.

— Average Cologuard cost per test was $123.

— Precision Oncology proforma revenue increased 14% to $119.1 million.

— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.

— FY2020 Screening revenue is expected to be $1.125-1.15 billion.

— FY2020 Precision Oncology revenue is expected to be $485-495 million.

— EXAS shares gained 1.2% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Earnings: Highlights of Bed Bath & Beyond (BBBY) Q1 report

Home furnishing retailer Bed Bath & Beyond (NASDAQ: BBBY) has reported a net loss for the first quarter of 2022 when the company’s revenues declined by 25%. Net earnings, adjusted

Mattel (MAT): Here are a few points to keep in mind if you are considering this toymaker

Shares of Mattel Inc. (NASDAQ: MAT) have gained 1% year-to-date and 6% over the past 12 months. The company delivered double-digit growth in sales and improved profitability for its most

Prologis (PLD) set for long-term gains from high e-commerce demand

The ripples of the COVID-driven e-commerce boom are being felt beyond the retail industry, and the other sectors influenced by it include transportation and real estate. The high demand for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top